Patents Assigned to Arrowhead Madison Inc.
  • Patent number: 9481661
    Abstract: We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: November 1, 2016
    Assignee: Arrowhead Madison, Inc.
    Inventors: Andrei V Blokhin, David B Rozema, Jonathan D Benson, Jeffrey C Carlson
  • Patent number: 9345775
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: May 24, 2016
    Assignee: Arrowhead Madison Inc.
    Inventors: David L Lewis, David B Rozema, Darren H Wakefield
  • Patent number: 9249179
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: February 2, 2016
    Assignee: Arrowhead Madison Inc.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Eric A. Kitas, Peter Mohr, Ingo Roehl, Linda Valis, David B. Rozema, David L. Lewis, Darren H. Wakefield
  • Patent number: 9107957
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: August 18, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: David B Rozema, David L Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Röhl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Günther Ott, Andrei V Blokhin, Jonathan D Benson, Jeffrey C Carlson
  • Patent number: 9089611
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: July 28, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H Wakefield, Nicholas A Rossi, Dan Sheik
  • Patent number: 9011919
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 21, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Eric Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Publication number: 20150104408
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Application
    Filed: November 25, 2014
    Publication date: April 16, 2015
    Applicant: ARROWHEAD MADISON INC.
    Inventors: Darren H. Wakefield, Nicholas A. Rossi, David B. Rozema, Lauren J. Almeida, Anthony L. Perillo-Nicholas
  • Patent number: 8933047
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: January 13, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Nicholas Rossi, Lauren Almeida, Anthony L. Perillo-Nicholas
  • Patent number: 8932572
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: January 13, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H. Wakefield, Nicholas Rossi, Dan Sheik
  • Patent number: 8809293
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: August 19, 2014
    Assignee: Arrowhead Madison Inc.
    Inventors: Daniel Chin, Jochen Deckert, Markus Hossbach, Matthias John
  • Patent number: 8802773
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 12, 2014
    Assignee: Arrowhead Madison Inc.
    Inventors: David B Rozema, David L Lewis, Darren H Wakefield, Eric A Kitas, Philipp Hadwiger, Jon A Wolff, Ingo Roehl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Guenther Ott, Andrei V Blokhin, Jeffrey C Carlson, Jonathan D Benson
  • Publication number: 20140128584
    Abstract: We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.
    Type: Application
    Filed: May 31, 2012
    Publication date: May 8, 2014
    Applicant: ARROWHEAD MADISON INC.
    Inventors: Andrei V. Blokhin, David B. Rozema, Jonathan D. Benson, Jeffrey C. Carlson
  • Patent number: 8658211
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible or labile linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: February 25, 2014
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jason Klein, So Wong, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20130317079
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Application
    Filed: August 23, 2012
    Publication date: November 28, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: Darren H. Wakefield, David B. Rozema, Nicholas Rossi, Lauren Almeida, Anthony L. Perillo-Nicholas
  • Patent number: 8541548
    Abstract: The present invention is directed compounds for reversibly modification of biologically active molecules. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: September 24, 2013
    Assignee: Arrowhead Madison Inc.
    Inventor: David B. Rozema
  • Publication number: 20130245091
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Application
    Filed: September 14, 2012
    Publication date: September 19, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Eric A. Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Patent number: 8501930
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: August 6, 2013
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffmann, Kerstin Jahn-Hofmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl
  • Publication number: 20130190484
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 25, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David Rozema, David Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Roehl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Guenther Ott, Andrei Blokhin, Jeffrey Carlson, Jonathan Benson
  • Publication number: 20130121954
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Application
    Filed: August 23, 2012
    Publication date: May 16, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: Darren H. Wakefield, Nicholas A. Rossi, Dan Sheik
  • Patent number: 8426554
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: April 23, 2013
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffmann, Kerstin Jahn-Hoffmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl